Functional Imaging and Peptide Receptor Radionuclide Therapy for Pancreatic Neuroendocrine Tumor
The Korean Journal of Pancreas and Biliary Tract. 2021;26(1):10-14 
Editorial: peptide receptor radionuclide therapy as neoadjuvant therapy for resectable or potentially resectable pancreatic neuroendocrine neoplasms
Surgery. 2018;163(4):768-769
Therapy‐related chronic myeloid leukemia in a patient receiving peptide receptor radionuclide therapy for pancreatic neuroendocrine tumor
Cancer Reports. 2020;3(5):
Large cardiac metastasis from pancreatic neuroendocrine tumor and response to peptide receptor radionuclide therapy with 177Lu-DOTATATE
Journal of Nuclear Cardiology. 2018;27(1):340-341
Peptide Receptor Radionuclide Therapy and the Treatment of Gastroentero-pancreatic Neuroendocrine Tumors: Current Findings and Future Perspectives
Nuclear Medicine and Molecular Imaging. 2018;52(3):190-199
Peptide receptor radionuclide therapy for neuroendocrine tumours
Clinical and Translational Imaging. 2018;6(2):101-111
Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE; Differences in Tumor Dosimetry, Vascularity and Lesion Metrics in Pancreatic and Small Intestinal Neuroendocrine Neoplasms
Cancers. 2021;13(5):962
Improving quality of life in patients with pancreatic neuroendocrine tumor following peptide receptor radionuclide therapy assessed by EORTC QLQ-C30
European Journal of Nuclear Medicine and Molecular Imaging. 2017;45(1):38-46
Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors
Nuclear Medicine Therapy. 2019;43-64
SUN-914 Peptide Receptor Radionuclide Therapy for an Inoperable Small Cell Neuroendocrine Tumor in the Philippines
Journal of the Endocrine Society. 2020;4(Supplement_1):